ArticleAdvances in therapy2025
Five Data-Informed Principles for Advancing Inclusive Research in Clinical Trials: A Pharma Perspective.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancing inclusive research (AIR) in clinical trials requires frameworks and metrics for assessing real-world data and measuring population science. Because different factors drive health inequities and variables in measuring population science, relying on one metric for measuring progress may have limitations. Five principles (5Ps) are proposed for AIR globally that form the basis for a data-informed framework to measure and systematically define inclusive research to ensure rigor and benchmarking within organizations and across the broader sector. The first principle addresses biological, genetic, and population science considerations and their responsible use as data elements. The second principle pertains to using data to inform global region, country, and site placement, which includes geographical proportionality in trial enrollment, enabled access and commercialization strategies, and representative real-world demographic representation. The third principle is developing a data-informed and user-informed approach to end-to-end inclusive trial design. The fourth principle integrates patient-reported data collection standards and initiatives supporting complete and consistent clinical trial collection. The fifth principle enables trial access by demonstrating trustworthiness, improving patient navigation, and providing assistance programs. These 5Ps can be used as an end-to-end measurable framework using reference metrics, reproducible data, and methodologies for AIR in clinical development.Infographic available for this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.